Phase 2 Macular Degeneration Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 50 or older who are able to give their agreement to participate and follow the study's requirements
- People who have a specific type of vision loss called geographic atrophy (GA) caused by dry age-related macular degeneration (AMD), where the damaged area does not affect the central part of the retina — this must be confirmed by a specialist reading centre
- People whose area of retinal damage falls within a specific size range, measured using a special eye imaging technique (confirm with trial site for exact details)
- People who still have a minimum level of vision in the eye being studied — roughly the ability to read the top few lines of a standard eye chart
- People whose eye pressure in the study eye is within a normal range
Who may not be able to join:
- People who have recently taken part in certain other eye treatment studies or trials
- Women who are pregnant or currently breastfeeding
- People with a high degree of short-sightedness or an eye that is longer than a certain measurement
- People who have previously received treatment for AMD, or who have a related condition involving abnormal blood vessel growth in the study eye
- People who have had or currently have a condition involving inflammation inside the eye called uveitis
- People who have recently received a specific type of medication that targets the complement system (part of the immune system)
- People currently using certain medications that are not permitted in this trial, including experimental treatments or therapies that suppress the immune system
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Dr. Andrew Chang, Sydney Retina Clinic & Day Surgery
Phone: +886 (2) 2790-6566
Australian sites
+61 2 9570 1622
+61 2 9221 3755
+61 3 6334 0000
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
3 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Number of Participants with Treatment-Emergent Adverse Events (TEAEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.